The transactivator of transcription, Tat, of human immunodeficiency virus type 1 (HIV-1) is required for viral replication. Inhibition of Tat function could have the potential to keep integrated provirus in dormancy. In the presence of Tat, Ro 24-7429, an analog of Ro 5-3335, inhibited expression of indicator genes controlled by the HIV-1 long terminal repeat promoter in transient transfection assays and in a constitutive cell line at noncytotoxic concentrations. Reduction of steady-state mRNA of the indicator gene by the compound correlated with reduction of the gene product in the constitutive cell line. Ro 24-7429 has broad activity against several strains of HIV-1 in different cell lines, peripheral blood lymphocytes, and macrophages (IC90 = 1-3 IAM). Importantly, Ro 24-7429 inhibited viral replication in both acute and chronic infection in vitro, a characteristic expected of a Tat antagonist and not shared by viral reverse transcriptase inhibitors. Consistent with this, the compound reduced cellassociated viral RNA and proteins and partially restored cell-surface CD4 in chronically infected cells. After 2 years of continued weekly passage of the virus in fresh CEM cells grown in the presence of the compound at 1 or 10 ,iM, the virus did not develop resistance to the drug. These results indicate that the compound's action might involve a cellular factor.
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Transcriptional regulation is employed by many types of viruses to control replication. Virally encoded regulators of transcription [e.g., EIA of adenovirus, VP16 and ICP4 of herpes simplex virus, and Tat of human immunodeficiency virus (HIV)] (1-6) can temporally control viral transcription and thereby up-regulate expression of a subset of viral genes crucial at certain stages of viral replication. These viral transcriptional regulators do not have cellular counterparts (or homologs) and therefore represent potentially selective antiviral targets. In particular, those expressed early in the replication cycle (e.g., ICP4 and Tat) to control transcription of other viral genes are attractive targets for antiviral agents directed against chronic viral infection. Such agents would have the potential to keep the virus in dormancy. Furthermore, these regulators interact with cellular transcription factors in infected cells. Mutations in these regulators that antagonize the interaction could be lethal to the viruses. Therefore, antiviral agents targeted at the function of these regulators might circumvent resistance commonly observed for available antiviral agents.
Tat of HIV-1 is required for viral replication (5, 6) . The protein transactivates transcription from the HIV LTR promoter by targeting a nascent RNA sequence [transactivation The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. response sequence (TAR)] immediately downstream from the transcription start site (7) (8) (9) . Destruction of the translation initiation codon of the protein by mutation renders the provirus nonreplicative (10); addition of Tat to culture media of cells harboring the defective provirus stimulates viral antigen production many thousandfold (11) . TAR RNA forms a stem-loop structure (12) , and in vitro studies have shown that Tat binds to a bulge in the stem (13) (14) (15) (16) . The functional mechanism of Tat appears to be predominantly through transcriptional elongation (9, 11, (17) (18) (19) (20) (21) . In the absence of Tat, transcription complexes that initiate at the HIV-1 LTR promoter could not read the DNA template to completion. Effects of Tat on transcriptional initiation have also been demonstrated with heterologous gene constructs (18, 19) . TAR RNA is present in all mRNAs of HIV-1; Tat apparently could also influence posttranscriptional events of these mRNAs in some cell types (22, 23) .
We reported previously the discovery and characterization of an HIV-1 Tat antagonist, . Animal studies revealed some toxicity of this compound. Based on this lead structure, nearly 400 analogs were synthesized. In vitro evaluation of one such analog, Ro 24-7429, is reported here.
This compound is active io acute and chronic infection and has a broad spectrum of activity against different strains of HIV-1 and HIV-2 in laboratory cell lines as well as peripheral blood lymphocytes (PBLs) and macrophages. In addition, the compound partially restored cell-surface CD4 in chronically infected cells, and the virus remained sensitive to this compound after prolonged exposure in vitro.
MATERIALS AND METHODS
Ro 24-7429, 7-chloro-N-methyl-5-(JH-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine, was synthesized from by reaction with methylamine in the presence of titanium tetrachloride. Reporter gene constructs, pBC12/HIV/SeAP and pBC12/RSV/SeAP, and the Tat expression plasmid, pBC12/HIV/Tat, have been reported (25 (24, 25) .
The anti-Tat assay was also performed with a constitutive cell line, HL3T1, that carries an integrated HIV-1 LTRdriven chloramphenicol acetyltransferase (CAT) gene (26) . Cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1 mM glutamine. Recombinant Tat was purified according to a published procedure (27) Anti-HIV Testing. High titer virus stocks of HIV-1 NlT strain were grown in CD4+ CR10 cells in RPMI 1640 medium (GIBCO) supplemented with 5% fetal bovine serum. HTLV-IIIB, RF, and UC-1 (HIV-2) strains of virus were similarly grown in H9 cells.
PBLs were isolated from seronegative donors using Ficoll/ Hypaque gradients and activated with interleukin 2 (10-20 units/ml of Lymphocult from Biotest, Denvil, NJ) and phytohemagglutinin (10-20 units/ml; Difco) for 2 days before infection with virus. Monocyte-derived macrophages were prepared by adherence to fibronectin and to plastic (29) .
Infection and drug treatment of CEM, Jurkat, C8166, and H9 cells were carried out as described (24) . Cell-associated viral RNA was quantitated with an RNARNA hybridization/ reversible target capture procedure (30) . Viral antigens were measured by the percentage of cells stained with antibodies from AIDS patients or a p24 ELISA (Coulter). Cytotoxicity of the drug in noninfected cells was measured by the tetrazolium-based MTT assay (31) . HT4-6C cells (HeLa cells expressing CD4 on the cell surfaces) were used for plaque reduction assay (32) of patient isolates, A012 and A018 (33), and LAV-1LAI (formerly LAV-1BRu) and LAV-2ROD strains of HIV.
For assays with chronically infected cells, CR10 cells resistant to the cytopathic effects of HIV-1 (34) were infected with NlT strain virus (35) and maintained in the laboratory as virus producers. p24 antigen and cell-associated viral RNA quantitation were performed on day 3 after addition of the drug. Alternatively, the low-cytopathic virus N1T-E strain (35) was used to infect CEM cells. Eight to 9 weeks after the initiation of the infection, the drug was added, and assays for virus replication were performed as described above.
RESULTS
The transient transfection assay employing the indicator gene secreted alkaline phosphatase (SeAP) was designed as a high throughput screen for compounds that specifically inhibited Tat-mediated transactivation of HIV-1 LTR (24, 25 or an inhibitor of alkaline phosphatase. Complete inhibition of SeAP expression was not found in these transient transfection assays. This was due to the assay protocol in which Ro 24-7429 was added 24 hr after cells were transfected. By that time, SeAP mRNA and enzymatic activity (stable in culture media at 37°C for several days) were already detected.
Tat transactivated SeAP activity 30-to 60-fold in this transfection assay; however, the increase in steady-state SeAP mRNA [selected for poly(A)+] was only 3-to 6-fold, with the remaining -10-fold transactivation apparently occurring posttranscriptionally (data not shown). Similar observations were reported by B. Cullen (22) . As (Fig. 2) Ro 24-7429 inhibited viral replication in chronically infected cells (Table 2) . Two types of chronic culture were employed for the assay: (i) CR10 cells resistant to the cytopathic effect of HIV-1 (34) and infected with the highly replicative and cytopathic NiT strain virus (35) , and (ii) CEM cells infected with the less cytopathic N1T-E strain virus (35) . The CR10 chronic culture was kept in the laboratory as a viral producer. Ro 24-7429 effectively suppressed viral replication after a 3-day treatment ofboth types of chronic cultures when cell-associated viral RNA and p24 released into culture media were measured. Since chronically infected CR10 cells lost their cell-surface CD4 molecules (see below), superinfection could not occur. Reduction in cell-associated viral RNA by the drug was a result of inhibition of transcription from integrated provirus, a result similarly found in the constitutive cell line HL3T1 described above. Higher drug concentrations were required to inhibit the highly replicative and cytopathic NiT strain compared to the less cytopathic N1T-E strain.
HIV-1 replication causes intracellular retardation of CD4 and prevents cell-surface expression of the molecules (38, 39) . This is due to the association of CD4 with viral gpl60. A consequence of inhibiting viral RNA and protein production by Ro 24-7429 was partial restoration of cell-surface CD4 as demonstrated by staining with CD4-specific monoclonal antibody (Table 3) . At a 10 ,uM drug concentration, a 100-fold reduction in viral antigen production was observed with a concomitant 39% restoration of cell-surface CD4. These data indicated that in the chronic culture, intracellular gpl60 molecules were in excess of the number of CD4 molecules.
Emergence of resistant HIV-1 in vitro and in treated patients has been reported for two classes of inhibitors to the viral reverse transcriptase, the nucleoside analogs (3'-azido-3'-deoxythymidine and dideoxyinosine) (33, 41) A more important question is whether HIV-1 could develop resistance to Ro 24-7429. For 3'-azido-3'-deoxythymidine, dideoxyinosine, Nevirapine, and L697,639, there are striking similarities in resistant viral isolates from the clinic and from the laboratory, in both gene mutation and relative length of time needed for the virus to emerge (33, (41) (42) (43) . Therefore, in vitro viral resistance might be predictive of clinical outcome. We conducted studies to investigate the Similar to other parts of the HIV-1 genome, the Tat sequence is subjected to frequent mutation (50) . However, Tat functions in a transcription complex, which includes basal and cell-type specific transcription factors (51). Tat may collaborate or interact with these cellular factor(s) to exert its function. In fact, several such factor(s) have been suggested (44, 45) . Since mutations in a cellular protein are rare, a mutation in Tat that affects interaction with cellular proteins could render Tat nonfunctional and thereby lethal to the virus. Ro 24-7429 antagonizes Tat function but its direct target is not known at the present. The lack ofviral resistance to the drug could imply involvement of a cellular protein in Tat function and/or drug action. Such a mode ofaction is also supported by our earlier findings on Ro 5-3335. The drug inhibited =95% of CAT expression in HL3T1 cells at 1 PM, irrespective of a 25-fold increase of recombinant Tat in the culture medium (52) , an indication that Tat was not the limiting factor for the action of the drug.
To our knowledge, the Tat antagonists Ro 5-3335 and Ro 24-7429 are the first drugs discovered through their inhibitory action on gene transcription. Recently several drugs that are already in clinical use for other diseases have also been found to inhibit gene transcription (e.g., cyclosporin A, FK506, and glucocorticoids) (53, 54) . We expect that such a therapeutic approach would continue to be explored, and random screening ofcompounds, similar to the one described here, could be employed. After pharmacokinetic and animal toxicological evaluations, is currently in clinical trials.
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